Several clinical trials, such as the GEOMETRY mono-1 trial and the VISION trial, are evaluating other TKIs like capmatinib and tepotinib in MET exon 14-mutated NSCLC and have shown promising results [12,121]. This evidence concerns the gene MET and non-small cell lung carcinoma.